- Digital twins for trial efficiency
- Concentrates on clinical trials depth over broad coverage
- Scales to organization-wide healthcare rollouts
Unlearn.AI
Digital twins for clinical trial efficiency
SF7.4
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Assess trial protocol feasibilityTrial sponsors and biostatistics teams
Assess trial protocol feasibilityTrial sponsors and biostatistics teams
Best for
Trial sponsors and biostatistics teams
Pricing
Custom
SoftFinders Score
7.4 / 10
Overview
What is Unlearn.AI?
Unlearn.AI is an AI company creating digital twins of trial participants to support more efficient clinical trial designs. The product is positioned around research operations, evidence generation, and trial workflow rather than guaranteed trial outcomes, and research governance and oversight remain essential parts of any clinical program. Buyers should confirm data access model, study design support, regulatory framing, and reporting depth before adopting across active research operations and trial portfolios at scale.
Unlearn.AI works best for trial sponsors and biostatistics teams, and its edge is digital twins for trial efficiency. The honest trade-off here: methods require regulatory and statistical buy-in. Pricing is sales-led and scoped per buyer rather than posted publicly. Run a small pilot to confirm fit before committing to a wider rollout.
KEY FEATURES
What you get out of the box
Federated Learning
Federated learning across distributed data
Recruitment Support
Supports recruitment for active trials
Trial Matching
Matches patients to relevant clinical trials
Real World Evidence
Generates rapid real-world evidence studies
Cohort Discovery
Discovers patient cohorts across data
Protocol Feasibility
Assesses protocol feasibility against data
USE CASES
Where teams put it to work
Assess trial protocol feasibility
Run federated research across institutions
Support trial recruitment workflows
Match patients to relevant trials
Generate real-world evidence studies
Discover patient cohorts across data
Editorial Take
What we like, and what to verify
- Methods require regulatory and statistical buy-in
- Recruitment outcomes still depend on study design
- Pricing is sales-led and needs scoping upfront
Screenshots
A look inside
Alternatives
Tools to consider next
Saama SF 7.5
Why consider it
AI analytics across clinical trial data
Sully.ai SF 7.6
Why consider it
All-in-one AI scribe and clinician assistant
Tali AI SF 7.5
Why consider it
Voice AI scribe with built-in medical search
Doximity GPT SF 7.4
Why consider it
Free clinical writing assistant for verified physicians
FAQ